SEC Filing Summary: Spherix Incorporated (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Spherix Incorporated (formerly Biospherics Incorporated) for the period ended March 31, 2004. The company operates through two primary segments: InfoSpherix, which provides contact center and reservation services (primarily for government clients), and BioSpherix, which develops proprietary biotechnology products, notably the sweetener tagatose. As of April 30, 2004, there were 11,957,225 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Revenue | $5,052,634 | $4,420,782 |
| Net Loss | $(547,401) | $(686,388) |
| Loss Per Share (Diluted) | $(0.05) | $(0.06) |
| Cash and Equivalents | $4,657,244 | $8,923,534 (End of Q1 2003) |
| Working Capital | $6.8 million | $5.0 million (Dec 31, 2003) |
| Bank Line of Credit Used | $1,946,540 | $1,716,743 (Dec 31, 2003) |
| Net Cash Used in Operating Activities | $(1,806,873) | $(19,277) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $632,000 (14%) year-over-year, driven largely by new government contracts in the InfoSpherix segment.
- Cost Increases: Direct contract and operating costs rose 21% ($679,000), outpacing revenue growth due to startup costs for new contracts and overhead increases from relocating the Cumberland, Maryland office.
- Expense Reductions: Selling, general, and administrative (SG&A) expenses decreased 13% ($174,000) due to reduced legal fees following a November 2003 arbitration settlement. R&D expenses dropped 54% ($57,000) due to fewer contracted studies.
- Acquisition: On March 1, 2004, the company acquired assets of Daksoft, Inc. (ReserveIt business) for $700,000 cash plus 43,029 shares of common stock, adding six government reservation contracts.
- Capital Raise: Financing activities provided $4.3 million, primarily from the exercise of 500,000 warrants by an institutional investor for approximately $3.5 million.
Outlook, Risks, and Management Commentary
- Contract Outlook: InfoSpherix won a multi-million dollar contract with the Federal Retirement Thrift Investment Board (FRTIB) starting July 2004. However, the company faces re-bidding on its two largest contracts (National Park Service and Maryland Information Center), which accounted for 54% of 2003 revenue.
- BioSpherix Strategy: Royalty revenue from tagatose remains modest ($1,400 in Q1 2004). Future growth depends on the licensee (SweetGredients) building a larger manufacturing plant, a decision expected later in 2004. The company is also commercializing "Naturlose" for non-food uses (toothpaste, mouthwash).
- Liquidity: The company has a $2 million bank line of credit with $53,000 remaining availability. Management believes current funds are adequate to meet obligations for the balance of 2004 even if the line is not renewed.
- Risks: Significant revenue concentration in government contracts subject to re-bidding; reliance on third-party licensees for BioSpherix product commercialization; and variable interest rate exposure on debt.
Investor Verification Checklist
- Verify the status and outcome of the re-bidding process for the National Park Service and Maryland Information Center contracts.
- Confirm the timeline and decision status regarding SweetGredients' construction of a new tagatose manufacturing plant.
- Monitor the renewal status of the $2 million Bank of America line of credit expiring June 30, 2004.
- Review the integration progress and revenue contribution of the newly acquired ReserveIt contracts.
- Assess the impact of the Cumberland office relocation on future operating cost structures.